[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)].
作者信息
Shi Yuankai, Sun Yan, Ding Cuimin, Wang Ziping, Wang Changli, Bai Chong, Bai Chunxue, Feng Jifeng, Liu Xiaoqing, Li Fang, Yang Yue, Shu Yongqian, Wu Milu, He Jianxing, Zhang Yiping, Zhang Shucai, Chen Gongyan, Luo Honghe, Luo Rongcheng, Zhou Caicun, Pang Qingsong, Hu Xingsheng, Zhao Hong, Zhao Qiong, Gu Aiqin, Ling Yang, Huang Cheng, Han Baohui, Jiao Shunchang, Jian Hong
机构信息
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing 100021, China.
The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2016 Jul 20;19(7):489-94. doi: 10.3779/j.issn.1009-3419.2016.07.12.
Abstract
摘要
相似文献
1
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment
(2016 version)].《中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）》
Zhongguo Fei Ai Za Zhi. 2016 Jul 20;19(7):489-94. doi: 10.3779/j.issn.1009-3419.2016.07.12.
2
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].《中国埃克替尼治疗非小细胞肺癌专家共识（2015年版）》
Zhongguo Fei Ai Za Zhi. 2015 Jul;18(7):397-400. doi: 10.3779/j.issn.1009-3419.2015.07.01.
3
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).一项关于埃克替尼治疗晚期非小细胞肺癌（NSCLC）的单臂、多中心、安全性监测的IV期研究。
Lung Cancer. 2014 Nov;86(2):207-12. doi: 10.1016/j.lungcan.2014.08.014. Epub 2014 Sep 16.
4
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.在中国，吉非替尼、埃克替尼和培美曲塞为基础的化疗作为晚期非小细胞肺癌一线治疗的成本效益分析
Oncotarget. 2017 Feb 7;8(6):9996-10006. doi: 10.18632/oncotarget.14310.
5
Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.埃克替尼对不同表皮生长因子受体（EGFR）表型的晚期非小细胞肺癌的影响。
Cell Biochem Biophys. 2014 Sep;70(1):553-8. doi: 10.1007/s12013-014-9955-y.
6
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.厄洛替尼对比吉非替尼用于经治的晚期非小细胞肺癌（ICOGEN）：一项随机、双盲、III 期非劣效性试验
Lancet Oncol. 2013 Sep;14(10):953-61. doi: 10.1016/S1470-2045(13)70355-3. Epub 2013 Aug 13.
7
Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.厄洛替尼对比全脑放疗用于表皮生长因子受体突变型非小细胞肺癌伴多发脑转移患者（BRAIN）：一项多中心、三期、开放标签、平行、随机对照临床试验。
Lancet Respir Med. 2017 Sep;5(9):707-716. doi: 10.1016/S2213-2600(17)30262-X. Epub 2017 Jul 19.
8
Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer.埃克替尼，一种选择性表皮生长因子受体酪氨酸激酶抑制剂，用于治疗非小细胞肺癌。
Future Oncol. 2015;11(3):385-97. doi: 10.2217/fon.14.249.
9
[Clinical effect of icotinib in treatment of elderly advanced non-small cell lung cancer patients with EGFR mutations].埃克替尼治疗老年晚期表皮生长因子受体基因突变非小细胞肺癌患者的临床疗效
Zhonghua Zhong Liu Za Zhi. 2019 Feb 23;41(2):152-153. doi: 10.3760/cma.j.issn.0253-3766.2019.02.014.
10
Icotinib: activity and clinical application in Chinese patients with lung cancer.埃克替尼：在中国肺癌患者中的活性及临床应用
Expert Opin Pharmacother. 2014 Apr;15(5):717-28. doi: 10.1517/14656566.2014.890183. Epub 2014 Mar 4.
引用本文的文献
1
Lung adenocarcinoma relapse with emerging EGFR mutation following complete response of small cell lung cancer warrants routine re-biopsy: A case report.小细胞肺癌完全缓解后出现EGFR突变的肺腺癌复发需要常规再次活检：一例病例报告
Front Oncol. 2022 Oct 26;12:1024655. doi: 10.3389/fonc.2022.1024655. eCollection 2022.
2
Circular RNA Eps15-homology domain containing protein 2 motivates proliferation, glycolysis but refrains autophagy in non-small cell lung cancer via crosstalk with microRNA-3186-3p and forkhead box K1.环状 RNA Eps15 同源结构域蛋白 2 通过与 microRNA-3186-3p 和叉头框蛋白 K1 的相互作用促进非小细胞肺癌的增殖、糖酵解，但抑制自噬。
Bioengineered. 2022 Mar;13(3):6464-6475. doi: 10.1080/21655979.2022.2031385.
3
The Public Health Insurance Coverage of Novel Targeted Anticancer Medicines in China-In Favor of Whom? A Retrospective Analysis of the Insurance Claim Data.中国新型靶向抗癌药物的公共医疗保险覆盖情况——惠及何人？基于保险理赔数据的回顾性分析
Front Pharmacol. 2021 Dec 21;12:778940. doi: 10.3389/fphar.2021.778940. eCollection 2021.
4
Nei Endonuclease VIII-like 2 Gene rs8191670 Polymorphism affects the Sensitivity of Non-small Cell Lung Cancer to Cisplatin by binding with MiR-548a.内核酸酶VIII样2基因rs8191670多态性通过与MiR-548a结合影响非小细胞肺癌对顺铂的敏感性。
J Cancer. 2020 Jun 6;11(16):4801-4809. doi: 10.7150/jca.47495. eCollection 2020.
5
Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer.用于治疗非小细胞肺癌的表皮生长因子受体酪氨酸激酶抑制剂的药物相互作用比较综述
Onco Targets Ther. 2019 Jul 9;12:5467-5484. doi: 10.2147/OTT.S194870. eCollection 2019.
6
Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis.培美曲塞联合放疗治疗肺腺癌脑转移患者的临床疗效与安全性评估
Oncol Lett. 2019 Mar;17(3):2874-2880. doi: 10.3892/ol.2019.9894. Epub 2019 Jan 4.
7
[Clinical Evaluation of A New Pathological Classification for
Non-small Cell Lung Cancer Based on Histogenesis of Bronchial Tree].[基于支气管树组织发生的非小细胞肺癌新病理分类的临床评估]
Zhongguo Fei Ai Za Zhi. 2018 Jul 20;21(7):530-535. doi: 10.3779/j.issn.1009-3419.2018.07.05.
8
[Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].[血清肿瘤标志物与晚期肺腺癌患者一线表皮生长因子受体酪氨酸激酶抑制剂疗效的相关性]
Zhongguo Fei Ai Za Zhi. 2017 Sep 20;20(9):589-597. doi: 10.3779/j.issn.1009-3419.2017.09.01.
9
[Circular RNA CircHIPK3 Promotes NCI-H1299 and NCI-H2170 Cell Proliferation through miR-379 and its Target IGF1].[环状RNA CircHIPK3通过miR-379及其靶标IGF1促进NCI-H1299和NCI-H2170细胞增殖]
Zhongguo Fei Ai Za Zhi. 2017 Jul 20;20(7):459-467. doi: 10.3779/j.issn.1009-3419.2017.07.04.
10
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.在中国，吉非替尼、埃克替尼和培美曲塞为基础的化疗作为晚期非小细胞肺癌一线治疗的成本效益分析
Oncotarget. 2017 Feb 7;8(6):9996-10006. doi: 10.18632/oncotarget.14310.
本文引用的文献
1
Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma.埃克替尼治疗肺腺癌脑转移患者的疗效和安全性。
Onco Targets Ther. 2016 May 17;9:2911-7. doi: 10.2147/OTT.S102472. eCollection 2016.
2
3
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
4
[China Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)].《中国晚期原发性肺癌诊治专家共识（2016年版）》
Zhongguo Fei Ai Za Zhi. 2016 Jan;19(1):1-15. doi: 10.3779/j.issn.1009-3419.2016.01.01.
5
Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology - Mainland China Subset Analysis of the PIONEER study.亚洲腺癌组织学类型晚期非小细胞肺癌患者表皮生长因子受体突变的分子流行病学——中国大陆地区PIONEER研究的亚组分析
PLoS One. 2015 Nov 23;10(11):e0143515. doi: 10.1371/journal.pone.0143515. eCollection 2015.
6
[China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)].《中国埃克替尼治疗非小细胞肺癌专家共识（2015年版）》
Zhongguo Fei Ai Za Zhi. 2015 Jul;18(7):397-400. doi: 10.3779/j.issn.1009-3419.2015.07.01.
7
[Standards for the diagnosis and treatment of primary lung cancer (2015 version) in China].《中国原发性肺癌诊疗规范（2015年版）》
Zhonghua Zhong Liu Za Zhi. 2015 Jan;37(1):67-78.
8
9
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).一项关于埃克替尼治疗晚期非小细胞肺癌（NSCLC）的单臂、多中心、安全性监测的IV期研究。
Lung Cancer. 2014 Nov;86(2):207-12. doi: 10.1016/j.lungcan.2014.08.014. Epub 2014 Sep 16.
10
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).一项针对亚洲晚期非小细胞肺癌腺癌组织学患者中表皮生长因子受体突变的前瞻性分子流行病学研究（PIONEER）。
J Thorac Oncol. 2014 Feb;9(2):154-62. doi: 10.1097/JTO.0000000000000033.
Zotero 插件